Literature DB >> 9533550

Lineage-negative human leukocyte antigen-DR+ cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.

B Melichar1, C Savary, A P Kudelka, C Verschraegen, J J Kavanagh, C L Edwards, C D Platsoucas, R S Freedman.   

Abstract

The characteristics of antigen-presenting cells in carcinomas that involve the abdominopelvic cavity are unknown. Dendritic cells, a population of antigen-presenting cells, have been identified as lineage-negative human leukocyte antigen (HLA)-DR+ cells by two-color flow cytometry. We used this criterion to study the putative dendritic cells in ascites from 25 patients with peritoneal carcinomatosis. The mean proportion +/- SD of lineage-negative HLA-DR+ cells in ascites was 3.1 +/- 4.6% (range, 0.05-17.3%). Most lineage-negative HLA-DR+ cells expressed CD45RA or CD4 antigens. Dendritic cells had low proportions of CD80, CD11c, CD45RO, and CD58, suggesting that they were of low maturity. The proportion of lineage-negative HLA-DR+ cells in ascites of seven patients was significantly higher than the proportion in peripheral blood from the identical patients (4.5 +/- 5.7 versus 0.5 +/- 0.4; P < 0.05). In paired specimens of ascites and peripheral blood, the proportion of lineage-negative HLA-DR+ cells that coexpressed CD86 or CD58 was significantly lower in ascites than in peripheral blood, whereas a higher proportion of lineage-negative HLA-DR+ cells in ascites expressed CD4. Relative fluorescence intensity of HLA-DR+ was also lower in dendritic cells from ascites and blood from patients with carcinomatosis than it was in blood from normal donors. As an indicator of macrophage activation, the concentration of neopterin in ascitic fluid correlated negatively with the numbers of lineage-negative HLA-DR+ cells in ascites (Spearman correlation coefficient, -0.44; P = 0.05) correlated positively with the concentration of interleukin 10 in ascitic fluid (Spearman correlation coefficient, -0.40; P = 0.05). IFN-gamma and tumor necrosis factor alpha were also not detected. These findings suggest that certain factors associated with the tumor microenvironment might influence the number of these dendritic cells and their expression of function-associated markers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9533550

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

Review 1.  Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.

Authors:  R Hájek; A W Butch
Journal:  Med Oncol       Date:  2000-02       Impact factor: 3.064

Review 2.  Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes.

Authors:  Evemie Schutyser; Ann Richmond; Jo Van Damme
Journal:  J Leukoc Biol       Date:  2005-03-22       Impact factor: 4.962

3.  Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.

Authors:  B Melichar; M A Nash; R Lenzi; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 4.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

5.  Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer.

Authors:  Samir F Zohny; Salah T Fayed
Journal:  Med Oncol       Date:  2009-11-24       Impact factor: 3.064

6.  Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumour-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines.

Authors:  M A Nash; R Lenzi; C L Edwards; J J Kavanagh; A P Kudelka; C F Verschraegen; C D Platsoucas; R S Freedman
Journal:  Clin Exp Immunol       Date:  1998-05       Impact factor: 4.330

7.  Increased serum transforming growth factor-beta1 in human colorectal cancer correlates with reduced circulating dendritic cells and increased colonic Langerhans cell infiltration.

Authors:  A Huang; J W Gilmour; N Imami; P Amjadi; D C Henderson; T G Allen-Mersh
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

8.  Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Authors:  Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman
Journal:  J Transl Med       Date:  2006-04-07       Impact factor: 5.531

9.  Antibody-mediated depletion of immunosuppressive factors from ovarian carcinoma-associated ascites for investigation of paracrine versus autocrine effects.

Authors:  E Brencicova; S S Diebold
Journal:  J Immunol Methods       Date:  2017-01-31       Impact factor: 2.303

10.  Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC).

Authors:  Ralph S Freedman; Michael Deavers; Jinsong Liu; Ena Wang
Journal:  J Transl Med       Date:  2004-06-25       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.